Literature DB >> 10722504

Risk factors for recovery of ampicillin-sulbactam-resistant Escherichia coli in hospitalized patients.

K S Kaye1, A D Harris, H Gold, Y Carmeli.   

Abstract

Ampicillin-sulbactam resistance in Escherichia coli is an emerging problem. This study determined risk factors for the recovery of ampicillin-sulbactam-resistant E. coli in hospitalized patients. A case-control design was used to compare two groups of case patients with control patients. The first group of case patients consisted of patients from whom nosocomially acquired ampicillin-sulbactam-resistant E. coli strains were isolated, and the second group of case patients consisted of patients from whom ampicillin-sulbactam-susceptible E. coli strains were isolated. Control patients were a random selection among 5% of all patients admitted during the same time period. Risk factors analyzed included antimicrobial drug exposure, comorbid conditions, and demographics. Univariate and multivariate analyses were performed. Ampicillin-sulbactam-resistant E. coli strains were isolated from 175 patients, and ampicillin-sulbactam-susceptible E. coli strains were isolated from 577 patients. Nine hundred thirty-four control patients were selected. Exposure to penicillin antibiotics as a class and to ampicillin and ampicillin-sulbactam individually were the only significant, independent risk factors associated with the isolation of ampicillin-sulbactam-resistant E. coli (odds ratio [OR] = 2.32 [P < 0.001], OR = 3.04 [P = 0.02], and OR = 1.72 [P = 0.04], respectively), but they were not associated with the isolation of ampicillin-sulbactam-susceptible E. coli. Interestingly, exposure to piperacillin-tazobactam tended to protect against the isolation of E. coli strains resistant to ampicillin-sulbactam, but this did not reach statistical significance (OR = 0.13; P = 0.11).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10722504      PMCID: PMC89805          DOI: 10.1128/AAC.44.4.1004-1009.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Selection of controls in case-control studies. II. Types of controls.

Authors:  S Wacholder; D T Silverman; J K McLaughlin; J S Mandel
Journal:  Am J Epidemiol       Date:  1992-05-01       Impact factor: 4.897

Review 2.  Antibiotic resistance in bacteria.

Authors:  S G Amyes; C G Gemmell
Journal:  J Med Microbiol       Date:  1992-01       Impact factor: 2.472

3.  Antibiotic utilization and cost analysis in hospitalized patients with community-acquired pneumonia.

Authors:  G E Stein; S L Mantz
Journal:  Hosp Pharm       Date:  1995-02

Review 4.  The epidemiology of beta-lactamases.

Authors:  B Wiedemann; C Kliebe; M Kresken
Journal:  J Antimicrob Chemother       Date:  1989-11       Impact factor: 5.790

5.  Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group.

Authors:  R N Jones; M A Pfaller; G V Doern; M E Erwin; R J Hollis
Journal:  Diagn Microbiol Infect Dis       Date:  1998-03       Impact factor: 2.803

6.  Risk factors for nosocomial candiduria due to Candida glabrata and Candida albicans.

Authors:  A D Harris; J Castro; D C Sheppard; Y Carmeli; M H Samore
Journal:  Clin Infect Dis       Date:  1999-10       Impact factor: 9.079

7.  Frequency of inhibitor-resistant TEM beta-lactamases in Escherichia coli isolates from urinary tract infections in France.

Authors:  C Henquell; D Sirot; C Chanal; C De Champs; P Chatron; B Lafeuille; P Texier; J Sirot; R Cluzel
Journal:  J Antimicrob Chemother       Date:  1994-11       Impact factor: 5.790

8.  Comparative activity of cefoxitin, ampicillin/sulbactam, and imipenem against clinical isolates of Escherichia coli and Klebsiella pneumoniae.

Authors:  D L Shungu; S Ponticas; C J Gill
Journal:  Clin Ther       Date:  1989 May-Jun       Impact factor: 3.393

9.  Factors determining resistance to beta-lactam combined with beta-lactamase inhibitors in Escherichia coli.

Authors:  J A Reguera; F Baquero; J C Pérez-Díaz; J L Martínez
Journal:  J Antimicrob Chemother       Date:  1991-05       Impact factor: 5.790

10.  Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM beta-lactamases from clinical isolates of Escherichia coli.

Authors:  C Henquell; C Chanal; D Sirot; R Labia; J Sirot
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

View more
  19 in total

1.  Emergence of piperacillin/tazobactam-resistant Escherichia coli.

Authors:  I Mohammedi; S Tigaud; J P Tournadre
Journal:  Intensive Care Med       Date:  2000-10       Impact factor: 17.440

2.  Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs.

Authors:  T Spanu; F Luzzaro; M Perilli; G Amicosante; A Toniolo; G Fadda
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  Multicentre study of antimicrobial resistance and antibiotic consumption among 6,780 patients with bloodstream infections.

Authors:  U Frank; E M Kleissle; F D Daschner; L Leibovici; M Paul; S Andreassen; H C Schonheyder; R Cauda; E Tacconelli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-12       Impact factor: 3.267

4.  Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa.

Authors:  Keith S Kaye; Zeina A Kanafani; Ashley E Dodds; John J Engemann; Stephen G Weber; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

5.  Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome.

Authors:  Mario Tumbarello; Teresa Spanu; Maurizio Sanguinetti; Rita Citton; Eva Montuori; Fiammetta Leone; Giovanni Fadda; Roberto Cauda
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

6.  P1A recombinant beta-lactamase prevents emergence of antimicrobial resistance in gut microflora of healthy subjects during intravenous administration of ampicillin.

Authors:  Ann-Mari Tarkkanen; Tuula Heinonen; Rain Jõgi; Silja Mentula; Michel E van der Rest; Curtis J Donskey; Tuomas Kemppainen; Konstantin Gurbanov; Carl Erik Nord
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

Review 7.  Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance.

Authors:  Vered Schechner; Elizabeth Temkin; Stephan Harbarth; Yehuda Carmeli; Mitchell J Schwaber
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

Review 8.  Clinical role of beta-lactam/beta-lactamase inhibitor combinations.

Authors:  Nelson Lee; Kwok-Yung Yuen; Cyrus R Kumana
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Epidemiological risk factors for isolation of ceftriaxone-resistant versus -susceptible citrobacter freundii in hospitalized patients.

Authors:  Peter W Kim; Anthony D Harris; Mary-Claire Roghmann; J Glenn Morris; Arjun Strinivasan; Eli N Perencevich
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

10.  Variety of beta-lactamases produced by amoxicillin-clavulanate-resistant Escherichia coli isolated in the northeastern United States.

Authors:  Keith S Kaye; Howard S Gold; Mitchell J Schwaber; Lata Venkataraman; Youlin Qi; Paola C De Girolami; Matthew H Samore; Greg Anderson; J Kamile Rasheed; Fred C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.